Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
The only causative treatment for IgE-mediated allergies is allergen-specific immunotherapy. However, fewer than 5% of allergy patients receive immunotherapy because of its long duration and risk of allergic side effects. We aimed at enhancing s.c. immunotherapy by direct administration of allergen into s.c. lymph nodes. The objective was to evaluate safety and efficacy compared with conventional s.c. immunotherapy. In a monocentric open-label trial, 165 patients with grass pollen-induced rhinoconjunctivitis were randomized to receive either 54 s.c. injections with pollen extract over 3 years [cumulative allergen dose 4,031,540 standardized quality units (SQ-U)] or 3 intralymphatic injections over 2 months (cumulative allergen dose 3,000 SQ-U). Patients were evaluated after 4 months, 1 year, and 3 years by nasal provocation, skin prick testing, IgE measurements, and symptom scores. Three low-dose intralymphatic allergen administrations increased tolerance to nasal provocation with pollen already within 4 months ( P < 0.001). Tolerance was long lasting and equivalent to that achievable after standard s.c. immunotherapy ( P = 0.291 after 3 years). Intralymphatic immunotherapy ameliorated hay fever symptoms ( P < 0.001), reduced skin prick test reactivity ( P < 0.001), decreased specific serum IgE ( P < 0.001), caused fewer adverse events than s.c. immunotherapy ( P = 0.001), enhanced compliance ( P < 0.001), and was less painful than venous puncture ( P = 0.018). In conclusion, intralymphatic allergen administration enhanced safety and efficacy of immunotherapy and reduced treatment time from 3 years to 8 weeks.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The major advantages of this route of allergen application are the markedly reduced duration of immunotherapy treatment (both time spent and number of visits) and the much lower amount of allergen required to achieve results.”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [1716]
In the citing paper
“Clinical trials have illustrated that a reduction in AR symptoms can be achieved with just 3 doses of injected allergen, with a dosage interval of 1 month1716-1720 (Table IX.D.6).”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [1716]
In the citing paper
“In 2008, Senti et al.1716 compared ILIT to SCIT and not to placebo.”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [1716]
In the citing paper
“Most trials1716,1718-1721 used commercially available grass pollen or birch pollen allergen extract as the antigen.”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [1716]
In the citing paper
“Of the 6 trials published thus far, 5 have demonstrated clinical efficacy and safety.1716-1720”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [1716]
Citations
Cites
Allergen immunotherapy: Therapeutic vaccines for allergic diseases A WHO position paper
Bousquet, J., Lockey, R., & Malling, H.-J. (1998) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(98)70271-4 · Cited by 1,581
Long-Term Clinical Efficacy of Grass-Pollen Immunotherapy
Durham, S. R., Walker, S. M., Varga, E.-M., Jacobson, M. R., O'Brien, F., Noble, W., Till, S. J., Hamid, Q. A., & Nouri-Aria, K. T. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908123410702 · Cited by 1,373
Möller, C., Dreborg, S., Ferdousi, H. A., Halken, S., Høst, A., Jacobsen, L., Koivikko, A., Koller, D. Y., Niggemann, B., Norberg, L. A., et al. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.121317 · Cited by 1,065
Position Paper: Allergen standardization and skin tests
Dreborg, S., & Frew, A. (1993) · Allergy · doi:10.1111/j.1398-9995.1993.tb04756.x · Cited by 753
Allergen Immunotherapy: Therapeutic Vaccines for Allergic Diseases
Bousquet, J., Lockey, R., Malling, H. J., Alvarez-Cuesta, E., Canonica, G. W., Chapman, M. D., Creticos, P. J., Dayer, J. M., Durham, S. R., Demoly, P., et al. (1998) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)63136-5 · Cited by 736
Arbes Jr., S. J., Gergen, P. J., Elliott, L., & Zeldin, D. C. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.05.017 · Cited by 639 · cited 1×
“I allergies, such as allergic rhinoconjunctivitis and asthma, have become highly prevalent, affecting up to 35% of the population in westernized countries (1).”
BackgroundPajno, G. B., Barberio, G., De Luca, F., Morabito, L., & Parmiani, S. (2001) · Clinical & Experimental Allergy · doi:10.1046/j.1365-2222.2001.01161.x · Cited by 546
Varney, V. A., Gaga, M., Frew, A. J., Aber, V. R., Kay, A. B., & Durham, S. R. (1991) · BMJ · doi:10.1136/bmj.302.6771.265 · Cited by 384
Fibroblasts as Efficient Antigen-Presenting Cells in Lymphoid Organs
Kündig, T. M., Bachmann, M. F., DiPaolo, C., Simard, J. J. L., Battegay, M., Lother, H., Gessner, A., Kühlcke, K., Ohashi, P. S., Hengartner, H., et al. (1995) · Science · doi:10.1126/science.7761853 · Cited by 301
Self-citation(1993) · PubMed · Cited by 221
Research works printed but not linked: 1
- Epidemiology Surveys and Danske Equities (ALK-Abelló, Hørsholm, Denmark, 2005).
Cited by
Items 301–363 of 363
Marino, M. J., & Luong, A. (2017) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2017.08.014 · Cited by 1
Olivier, B. L. M., Meléndez, Á. P., & Verduzco, F. A. C. (2021) · Alergia, Asma e Inmunología Pediátricas · doi:10.35366/100111 · Cited by 1
Update zur Hymenopterengiftallergie
Helbling, A., & Müller, U. R. (2014) · CME · doi:10.1007/s11298-014-0005-2
ALLERGY TO PETS; MOLECULAR APPROACHES FOR IMPROVED DIAGNOSTICS AND VACCINATION
Nilsson, O. (2012) · Figshare
Immunothérapie jusqu’à quel âge ?
Martinat, Y., Wallaert, B., Didier, A. P., & Seferian, A. (2011) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(11)70091-x
Highlights on the EAACI–WAO Congress 2013
Ridolo, E., Montagni, M., Olivieri, E., & Canonica, G. W. (2013) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2013.828877
Emerging drugs for perennial allergic rhinitis
Passalacqua, G., & Ciprandi, G. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.746312
RECOMBINANT CAT AND MITE ALLERGENS AS TOOLS IN THE STUDY OF DIAGNOSIS AND TREATMENT OF ALLERGY
Saarne, T. (2009) · Figshare
Sestak, J. O. (2011) · KU ScholarWorks (The University of Kansas)
Guideline on allergen-specic immunotherapy in IgE-mediated allergic diseases
Fa, O. L. I. V. E. R. P., & Johannes Gutenberg-University (2014)
Immunogenicity of a mRNA-based vaccine encoding the House Dust Mite allergen Derp1
van Weijnen, A. (2014)
Immunologiske mekanismer og effektmåling ved spesifikk immunterapi (SIT) for bjørkepollenallergi
Amalathas, A. N. (2013) · NORA - Norwegian Open Research Archives
Therapeutic Immune Tolerance Approaches for the Treatment of Allergic Disease
Smarr, C. B., Getts, D. R., & Miller, S. D. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801577-3.00011-3
Novel Allergen Immunotherapy Routes
Klimek, L., Sperl, A., Senti, G., & Kündig, T. M. (2016) · Current Treatment Options in Allergy · doi:10.1007/s40521-016-0071-7
Self-citationBilò, M. B., & Bonifazi, F. (2011)
Chini, L., Monteferrario, E., Graziani, S., & Moschese, V. (2014)
Spezifische Immuntherapie/Hyposensibilisierung
Eben, R., Bellinghausen, I., Brockow, K., Fuchs, T., Ruëff, F., Saloga, J., & Przybilla, B. (2009) · Fortschritte der praktischen Dermatologie und Venerologie · doi:10.1007/978-3-540-77148-7_87
Allergische Erkrankungen in der Hals-Nasen-Ohren-Heilkunde
Heppt, M. V., & Heppt, W. J. (2016) · Springer eBooks · doi:10.1007/978-3-642-37203-2_35 · Cited by 1
Immune regulation by allergen immunotherapy
Maazi, H., & Shirinbak, S. (2012)
Neue Entwicklungen bei anti allergischen Therapien und Therapiekonzepten
Biedermann, T., Röcken, M., & Renz, H. E. (2016)
Innovative Formen der spezifischen Immuntherapie
Zieglmayer, P. U. (2017) · Der Hautarzt · doi:10.1007/s00105-017-3948-x
Designing distribution of adjuvants: Synthesis of lipidated nucleic acid adjuvant compounds
Bilbrough, T. (2017) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17148161
Update on Allergen Immunotherapy for Allergic Rhinitis: Drops, Tablets, or Shots?
Roxbury, C. R., & Lin, S. Y. (2017) · Current Otorhinolaryngology Reports · doi:10.1007/s40136-017-0159-z
Allergens for Immunotherapy―Present and Future Perspective―
Kuwabara, Y., Nagao, M., & Fujisawa, T. (2018) · Nihon Shoni Arerugi Gakkaishi The Japanese Journal of Pediatric Allergy and Clinical Immunology · doi:10.3388/jspaci.32.61
Subcutaneous Immunotherapy for Allergic Rhinitis and Asthma
Lin, C. H. (2018) · Springer eBooks · doi:10.1007/978-3-319-58726-4_40-1
Virus-like particles in der Prophylaxe und Immuntherapie allergischer Erkrankungen
Klimek, L., Kündig, T. M., Kramer, M. F., Guethoff, S., Jensen‐Jarolim, E., Schmidt‐Weber, C. B., Palomares, Ó., Mohsen, M. O., Jakob, T., & Bachmann, M. F. (2018) · Allergo Journal · doi:10.1007/s15007-018-1763-z
Self-citationAIT: Auf dem Weg zu optimierter Wirksamkeit und Verträglichkeit
Zieglmayer, P. U. (2019) · HNO Nachrichten · doi:10.1007/s00060-019-5825-y
Der Weg ist das Ziel – neue Applikationsverfahren der Allergenimmuntherapie
Pfützner, W. (2021) · Der Hautarzt · doi:10.1007/s00105-021-04869-3
(2009) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e328333c13c
(2009) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e32832c00ee
Spezifische Immuntherapie – Hyposensibilisierung
Friedl, T. K., Brehler, R., Darsow, U. G., Ruëff, F., Treudler, R., Werfel, T., & Przybilla, B. (2013) · Fortschritte der praktischen Dermatologie und Venerologie · doi:10.1007/978-3-642-24767-5_79
Ahlbeck, L., Ahlberg, E., rkander, J. B., Aldén, C., Papapavlou, G., Palmberg, L., m, U. N., Retsas, P., Nordenfelt, P., Togö, T., et al. (2020) · Authorea · doi:10.22541/au.159672621.14649755
Self-citationSubcutaneous Immunotherapy for Allergic Rhinitis and Asthma
Lin, C. H. (2019) · Springer eBooks · doi:10.1007/978-3-030-05147-1_40 · Cited by 1
AIT: Auf dem Weg zu optimierter Wirksamkeit und Verträglichkeit
Zieglmayer, P. U. (2019) · hautnah dermatologie · doi:10.1007/s15012-019-3039-z
Kortdurende desensibilisatietherapie voor hooikoorts
(2009) · Huisarts en Wetenschap · doi:10.1007/bf03085604
Klimek, L. (2009) · Springer eBooks · doi:10.1007/978-3-642-05010-7_8
Yadav, S., Singh, S., Mandal, P., & Tripathi, A. (2022) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2022.5151 · Cited by 1
Hesse, L., Elberink, J. N. G. O., van Oosterhout, A. J. M., & Nawijn, M. C. (2022) · Kompass Neumología · doi:10.1159/000525293
Current Developments in Allergen-Specific Immunotherapy: A Brief Review
Bartholazzi, M. G. B., Lodi, T. D. M., & Machado, O. L. T. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.106280
Adjuvants in Allergy: Elevating Efficacy
Mughal, T. (2016) · EMJ Allergy & Immunology · doi:10.33590/emjallergyimmunol/10313507
Developments and emerging technologies in allergic and immunologic disease management
Leung, N. Y. H., Wai, C. Y. Y., Shao, T., Chu, K. H., & Leung, P. S. C. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-95061-9.00007-2 · Cited by 1
Arce-Estrada, G. E., Arce-Estrada, J., Contreras‐Verduzco, F. A., & Espinosa‐Padilla, S. E. (2022) · Alergia, Asma e Inmunología Pediátricas · doi:10.35366/109664
Promising New Diagnostic and Treatment Modalities for Allergic Rhinitis
Barrett, T. F., & Roland, L. T. (2023) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2023.08.008
Intralymphatic Immunotherapy : A Novel Route to Ameliorate Allergic Rhinitis Due to Pollen
Ahlbeck, L. (2023) · Linköping University medical dissertations · doi:10.3384/9789180752527
Cho, M., Nguyen, V. T., Suami, H., Kraft, C. T., & Kraft, M. (2024) · Allergy · doi:10.1111/all.16379
Johansen, P., Flory, S., Šošić, L., Kündig, T. M., & Lang, C. C. (2024) · Journal of Dermatology Research · doi:10.46889/jdr.2024.5310
Self-citationProgress on Immunotherapy for Allergic Rhinitis
蒋, 运. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1551605
Tsai, S. J., Kapnick, S. M., Carey, S. T., McIlvaine, R. A., Rui, Y., Eppler, H. B., Shah, S., Bridgeman, C. J., Yanes, A. A., Black, S. K., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.10.026 · Cited by 2
Weinfeld, D., Westin, U., Hellkvist, L., Mellqvist, U.-H., Jacobsson, I., & Cardell, L.-O. (2020) · Figshare · doi:10.6084/m9.figshare.12211538
Weinfeld, D., Westin, U., Hellkvist, L., Mellqvist, U.-H., Jacobsson, I., & Cardell, L.-O. (2020) · Figshare · doi:10.6084/m9.figshare.12211622
Weinfeld, D., Westin, U., Hellkvist, L., Mellqvist, U.-H., Jacobsson, I., & Cardell, L.-O. (2020) · Figshare · doi:10.6084/m9.figshare.12211625
Weinfeld, D., Westin, U., Hellkvist, L., Mellqvist, U.-H., Jacobsson, I., & Cardell, L.-O. (2020) · Figshare · doi:10.6084/m9.figshare.12211547
Weinfeld, D., Westin, U., Hellkvist, L., Mellqvist, U.-H., Jacobsson, I., & Cardell, L.-O. (2020) · Figshare · doi:10.6084/m9.figshare.12211556
Weinfeld, D., Westin, U., Hellkvist, L., Mellqvist, U.-H., Jacobsson, I., & Cardell, L.-O. (2020) · Figshare · doi:10.6084/m9.figshare.12211565
Adjuvant Strategies to Improve the Efficacy of Allergen Immunotherapy
Tabynov, K., Tabynov, K., & Petrovsky, N. (2026) · Journal of Inflammation Research · doi:10.2147/jir.s546218
Future Directions of Allergen Immunotherapy
Stoller, E., Kong, K., & Franzese, C. B. (2026) · Current Otorhinolaryngology Reports · doi:10.1007/s40136-026-00550-2
Kars¹, A., & Ersun², I. (2026) · Research Square · doi:10.21203/rs.3.rs-9702744/v1
Wang, K., Tian, S., Qin, Y., Li, C., Li, C., Li, C., & Shi, J. (2026) · Acta Oto-Laryngologica · doi:10.1080/00016489.2026.2679182
Šošić, L., Flory, S., Lang, C. C. V., Widmer, E. C. J., Chabot, A., Schmid, J. M., Andermatt, T., Melillo, D., Hviid‐Vyff, B., Mardahl, M., et al. (2026) · Allergy · doi:10.1111/all.70463
Self-citationPatterson, A. M., Brooks, C. D., & Tate, C. J. (2026) · Allergy and Asthma Proceedings · doi:10.2500/aap.2026.47.260051
Fernandes, L. G. R., Lother, J. M., & Zollner, R. D. L. (2026) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2026.2716674
Almezher, M. U., Alharbi, F., Alshngeetee, A., Almugharriq, R. M., Alanazi, A. K., aljuaid, R., gharbi, R., Alamri, W. S., Mash, R. E., Alqaed, M. H. S., et al. (2026) · American Journal of Otolaryngology · doi:10.1016/j.amjoto.2026.104969
Metadata
- Authors
- Senti, G., Prinz Vavricka, B. M., Erdmann, I., Diaz, M. I., Markus, R., McCormack, S. J., Simard, J. J., Wüthrich, B., Crameri, R., Graf, N., Johansen, P., & Kündig, T. M.
- Affiliations
- University Hospital Zurich (CH)
- Unit for Experimental Immunotherapy, Department of Dermatology, and
- MannKind Corporation (United States) (US)
- Swiss Institute for Asthma and Allergy Research, 7270 Davos, Switzerland
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-11-18
- Volume
- 105
- Issue
- 46
- Pages
- 17908-17912
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2582048
- OpenAlex
- W1975755712
- Cited by
- 364
- References
- 26
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 14 · 2023: 22 · 2022: 26 · 2021: 18 · 2020: 21 · 2019: 12 · 2018: 18 · 2017: 23 · 2016: 24 · 2015: 19 · 2014: 35 · 2013: 30 · 2012: 26
- FWCI
- 12.08
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- National Science Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (114634, 310000)
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- allergen immunotherapy, subcutaneous immunotherapy, grass pollen allergy, rhinoconjunctivitis, allergic rhinitis, IgE-mediated allergy, lymph node injection, treatment duration, treatment safety, medication adherence
- MeSH terms
- Adolescent, Adult, Aged, Allergens, Desensitization, Immunologic, Female, Humans, Hypersensitivity, Immunoglobulin E, Immune Tolerance, Injections, Intralymphatic, Injections, Subcutaneous, Male, Middle Aged, Pain, Skin Tests, Time Factors, Treatment Outcome, Anti-Allergic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.